Missed Our Liver Cancer Lessons Webinar? Watch the Recording!

In our recent webinar, Dr. Jennifer Lai, and patient advocates Karen Hoyt and Susan Horava, discussed Liver Disease Prevention Through Nutrition. Check out the recording to learn how nutrition impacts liver disease, discover practical tips to support a healthy liver, and hear answers to some of the most common nutrition-related questions.

One Liver to Love Campaign wins the MUSE Creative Awards! 

We’re thrilled to share that the One Liver to Love campaign has won a Gold Award in the MUSE Creative Awards for its engaging TikTok video series featuring Bruce Bower! This recognition in the Social Media – Healthcare & Pharma category celebrates the campaign’s creative impact in raising liver cancer awareness through innovative storytelling and digital outreach.

Combining TACE with Systemic Therapies Improves Outcomes in Intermediate-Stage HCC

Two clinical trials have shown that adding systemic therapies to transarterial chemoembolization (TACE)—a standard treatment that delivers chemotherapy directly to liver tumors—can benefit patients with intermediate-stage hepatocellular carcinoma (HCC). In the LEAP-012 trial, TACE was combined with pembrolizumab (Keytruda) and lenvatinib (Lenvima), while the EMERALD-1 trial combined TACE with durvalumab (Imfinzi) and bevacizumab. Both studies found that patients who received these combination treatments lived significantly longer without their cancer progressing compared to those who received TACE alone, with progression-free survival extended to about 15 months versus 8 to 10 months. These results suggest that combining TACE with immunotherapy and targeted drugs could offer a more effective treatment option and potentially become a new standard of care for patients with intermediate-stage HCC.

New Drug Candidate Shows Promise Against MASLD and Liver Cancer in Preclinical Study 

Researchers are investigating new treatments for metabolic dysfunction-associated steatotic liver disease (MASLD), a condition linked to obesity and diabetes that increases the risk of liver cancer. A recent study published in Nature Aging highlighted a promising drug designed to eliminate senescent—or “zombie”—cells in the liver, which contribute to liver damage and cancer development in MASLD. In lab and animal studies, the drug successfully reduced liver fat, fibrosis, and tumor growth without causing the toxic side effects seen in previous senescent cell-targeting drugs. Although still in the early preclinical stage, this research points to a potential new approach for preventing liver cancer by treating the root causes of MASLD.

Proactive Protection of the Liver Health of Asian Americans

Did you know that everyone should be screened for Hepatitis B? This infection can slowly and quietly cause liver damage over the years, eventually leading to liver cancer in many cases. Certain communities, such as Asian Americans and Asian-American immigrants, have a higher risk of hepatitis B. Fortunately, hepatitis B infection is preventable with a vaccine and its progression can be managed with ongoing treatment, if needed after screening. Learn more about this in our recent blog post.